The Digital Metabolic Liver Disease Accelerator

Approximately 2-6% of people worldwide live with NASH. NASH is the buildup of fat in the liver, and if not managed properly can lead to cardiovascular disease and/or end-stage liver disease, at which point liver damage may be irreversible.

The digital Metabolic Liver Disease Accelerator will support 1-2 digital solutions with up to 100.000 USD to pilot their solutions with Novo Nordisk. We believe there is so much to be explored in this space and are therefore open to working with startups of all sizes, from pre-seed onwards. The deadline for application is May 15th, 2022

More information in the PDF below. 

Related Files

Back